Efficacy and Safety of USL for Dry Eye Disease

NCT06016010 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2023-09-11

No results posted yet for this study

Summary

The objective is to compare the USL and placebo in terms of efficacy and safety, and to determine the appropriate dosage.

Conditions

Interventions

DRUG

USL

500mg of Achyranthis Radix Extract

DRUG

USL Placebo

USL Placebo

Sponsors & Collaborators

  • Chan-Sik Kim

    lead OTHER_GOV

Principal Investigators

  • Chan-Sik Kim, PhD · Korea Institute of Oriental Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2025-12-31
Completion
2025-12-31

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06016010 on ClinicalTrials.gov